RELEVIUM TECHNOLOGIES INC. (TSX.V:“RLV”,
OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), is pleased to
provide an update on operations and continuous disclosure matters.
UPDATE ON ONGOING OPERATIONSOn
December 16, 2021, the Company announced it had delivered 127.5
million medical grade nitrile gloves, representing 100% of the
first of two PPE contracts that the Company had entered into for a
total value of CAD$11M. During the month of January 2022, the
Company delivered on CAD$1 million out of the CAD$5 million from
the second of the two PPE contracts announced on December 16, 2021.
The Company is pleased to announce that the product relating to the
remaining balance of the second contract is expected to be
delivered over the next four weeks as the product arrives from
overseas suppliers.
The Company’s sales from its nutraceutical
products continue to recover ground lost during the last two years
of the pandemic. As the supply chain recovers, the Company has been
able to supply through its online platforms within the established
limitations of each marketplace.
On November 23, 2021, the Company announced a
non-binding term sheet to acquire MED PPE, a company specializing
in medical supply distribution for the Canadian market. The Company
and the MED PPE have decided not to proceed with the proposed
transaction.
Aurelio Useche, CEO of Relevium stated:
“Although we have experienced supply chain disruptions relating to
shipping container availability and weather-related events in
Western Canada, we continue to fulfill the contracts for medical
gloves. At this rate we expect to complete the remaining contract
within the next four weeks”. Mr. Useche stated further: “Although
slow at times, we are feeling positive about the recovery rate of
our online sales for our leading brand Bioganix®. The Company is
preparing to relaunch the Bioganix® brand and introduce a few new
trending formulations”.
UPDATE ON MCTO AND AUDITED
STATEMENTSAs of today, the Company is still facing issues
of resource allocation from its current auditors and management
continues to work diligently on this matter in order to complete
the audit for the fiscal year ended June 30, 2021, as well as the
second and third quarter interim statements.
As disclosed in the Company's press release
dated November 1, 2021, the Company applied for and received a
management cease trade order ("MCTO") in respect of the late filing
of its annual financial statements for the year ended June 30,
2021, including the related management discussion and analysis, and
CEO and CFO certifications. Due to the fact that the audit process
is still not complete, the securities regulator has imposed a full
cease trade order (“CTO”) for the Company until its obligations for
continued disclosure are met. The CTO is expected to be lifted once
the Company completes the filing of its past-due financial
statements and associated management's discussion and analysis and
CEO and CFO certifications.
UPDATE TRADING HALT BY THE TSX VENTURE
EXCHANGEOn January 10, 2022 the TSX Venture Exchange (the
“Exchange”) halted trading in the Company's shares until such time
as the Company completes certain filings with the Exchange. The
Company continues to work with the Exchange to resolve the
outstanding filings so that the trading halt can be removed.
Management endeavours to provide updates to the
market as they become available.
Neither the
TSX Venture
Exchange nor its
Regulation Services Provider
(as that term
is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
About Relevium Technologies
Relevium Technologies Inc., is
a publicly traded company, focused on wellness and international
procurement, logistics, and delivery of PPE into the North American
marketplace. Utilizing trusted vendors and suppliers, and
integrating a comprehensive, state-of-the-art supply chain,
artificial intelligence, and blockchain technology, enables a
highly secure and compliant platform for delivery of PPE equipment
to governments, hospitals, foundations, and various institutions.
Cautionary
Note Regarding Forward-Looking StatementsThis release
includes certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian securities laws. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, assumptions or
expectations of future performance, including the satisfaction of
the supply of gloves under the supply agreements and the timing
thereof, the impact of the supply agreements disclosed herein on
the Company's financial results, the timing and ability of the
Company to complete the filing of the outstanding financial
statements, management's discussion and analysis and certifications
and rescind the CTO and the timing and completion of the filings
with the Exchange and the removal of the trading halt, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur".
Forward-looking statements are based on certain
material assumptions and analysis made by the Company and the
opinions and estimates of management as of the date of this press
release, including the ability of the Company to (i) complete the
supply of gloves under the supply agreements, (ii) complete the
filings necessary to rescind the CTO, (iii) agree to terms for the
proposed transaction with Med PPE and satisfy the conditions
associated with such transaction, (iv) successfully execute its
business plans, (v) maintain its expenses, (vi) navigate the
COVID-19 pandemic in a manner consistent with or better than its
ability and response to date. A description of additional risk
factors that may cause actual results to differ materially from
forward-looking information can be found in the Company’s
disclosure documents on the SEDAR website at www.sedar.com.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Although management of the Company has
attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. Readers
are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial outlook that are incorporated by reference herein,
except in accordance with applicable securities laws. We seek safe
harbour.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEOFor more information about this
press release: Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website: www.releviumtechnologies.com
Like us on FacebookFollow us on Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
過去 株価チャート
から 10 2024 まで 11 2024
Relevium Technologies (TSXV:RLV)
過去 株価チャート
から 11 2023 まで 11 2024